Stock Financial Ratios, Dividends, Split History

CRSP / CRISPR Therapeutics AG financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,926.06
Enterprise Value ($M)2,761.85
Book Value ($M)290.33
Book Value / Share6.15
Price / Book9.51
NCAV ($M)267.36
NCAV / Share5.67
Price / NCAV10.33
Share Statistics
Common Stock Shares Outstanding 40,592,248
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 46,976,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.36
Return on Assets (ROA)-0.20
Return on Equity (ROE)-0.29
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio24.42
Income Statement (mra) ($M)
Revenue From Related Parties4,760,000.00
Operating Income-64.65
Net Income-68.36
Earnings Per Share Basic-1.71
Earnings Per Share Basic And Diluted-1.71
Earnings Per Share Diluted-1.71
Cash Flow Statement (mra) ($M)
Cash From Operations-70.10
Cash from Investing-8.31
Cash from Financing-70.10
Identifiers and Descriptors
Central Index Key (CIK)1674416
Industry Groups

Split History

Stock splits are used by CRISPR Therapeutics AG to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Gene Editing Is Coming: Get In Front Of Sangamo Therapeutics's 'Irrational Extrapolation Event'

10h seekingalpha
The total addressable market for gene editing/therapy really is this big. And no one believes it. (2-0)

Your Daily Pharma Scoop: Tonix Progresses, J&J Succeeds, Quidel Is Cleared

2018-07-19 seekingalpha
Tonix Pharmaceuticals receives fast track designation for TNX-102 SL for treatment of agitation in alzheimer’s disease (50-0)

New Study Says DNA Damage From CRISPR-Cas9 Gene-Editing Has Been Underestimated

2018-07-17 biospace
Shares of CRISPR Therapeutics (-8 percent), Editas Medicine (-5 percent) and Intellia Therapeutics (-6.7 percent) are all plunging following the release of a report that claimed CRISPR-Cas9 gene editing may cause some dangerous side effects. (6-0)

A Single Study Is No Reason to Sell Crispr Stock | InvestorPlace

2018-07-16 investorplace
Crispr Therapeutics (NASDAQ:CRSP) is down on Monday after an article in today’s issue of Nature (one of the most-trusted, well-known scientific journals) raised concerns about Crispr’s gene-editing technology. As of this writing, Crispr stock is down 7.9%. (0-1)

UPDATE 1-CRISPR gene editing can cause risky collateral DNA damage - study

2018-07-16 reuters
LONDON (Reuters) - Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells. (6-1)

CUSIP: H17182108